NanoVibronix, Inc. (NASDAQ: NAOV), a medical technology company specializing in non-invasive therapeutic devices, is making waves after an independent study published in The Australian and New Zealand Continence Journal affirmed the effectiveness of its UroShield® device. The report highlights UroShield’s ability to significantly reduce catheter-associated urinary tract infections (CAUTIs) and blockages, marking a major breakthrough for patients with indwelling urinary catheters (IUCs).
The study showcased impressive outcomes among patients using UroShield, including:
- 86% reduction in UTI incidence
- 70% fewer catheter blockages
- 8% decrease in bladder irrigations
- 3% reduction in catheter changes
Additionally, clinicians reported improved overall catheter comfort and a reduced need for catheter-related interventions, which contributed to lower healthcare resource costs. The study found that implementing UroShield led to a 63.5% decrease in resource expenditure over five months, making a compelling case for its widespread adoption.
Brian Murphy, CEO of NanoVibronix, Inc., commented, “This study underscores the benefits of UroShield in enhancing patient care by reducing CAUTI incidence and catheter blockages, minimizing catheter complications and improving overall comfort. Notably, researchers found that UroShield required less nursing time, which eased workload demands and resulted in measurable cost savings for the healthcare provider.”
The post NanoVibronix’s UroShield® Gains Validation in Independent Study for UroShield, Shares Surge 60% appeared first on PRISM MarketView.
